U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT07591077) titled 'SGLT2 Adjunct in T1D' on May 09.

Brief Summary: Effect of Sodium-Glucose Cotransporter (SGLT) 2 Inhibitors on Diabetic Nephropathy Progression in Adolescents with Type 1 Diabetes Mellitus

Study Start Date: Nov. 20, 2024

Study Type: INTERVENTIONAL

Condition: Type 1 Diabetes Nephropathy, Diabetic

Intervention: DRUG: Empagliflozin (EMPA)

empagliflozin oral once daily

OTHER: Placebo

placebo

Recruitment Status: COMPLETED

Sponsor: Ain Shams University

Information provided by (Responsible Party): Nouran yousef, Ain Shams University

Published by HT Digital Content Services with permission from Health Daily Digest....